SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?

Pabel, Steffen; Hamdani, Nazha; Luedde, Mark; Sossalla, Samuel

Pabel, Steffen; Hamdani, Nazha; Luedde, Mark; Sossalla, Samuel.

Affiliation

Pabel S; Department of Internal Medicine II, University Medical Centre Regensburg, Regensburg, Germany.
Hamdani N; Department of Molecular and Experimental Cardiology and Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.
Luedde M; Department of Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Sossalla S; Department of Internal Medicine II, University Medical Centre Regensburg, Regensburg, Germany. samuel.sossalla@ukr.de.

Curr Heart Fail Rep ; 18(5): 315-328, 2021 10.

Article in En | MEDLINE | ID: mdl-34523061

Subject(s)

Diabetes Mellitus, Type 2; Heart Failure; Sodium-Glucose Transporter 2 Inhibitors; Diabetes Mellitus, Type 2/complications; Diabetes Mellitus, Type 2/drug therapy; Heart Failure/drug therapy; Humans; Sodium-Glucose Transporter 2 Inhibitors/pharmacology; Stroke Volume

Key words

HFpEF; HFrEF; Heart failure; SGLT2 inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors / Heart Failure Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Curr Heart Fail Rep Journal subject: CARDIOLOGIA Year: 2021 Type: Article Affiliation country: Germany

Fulltext

XML

PubMed Links

Search on Google